Various studies suggest that TGF-β1 activates PI3K/Akt/NF-kB/MMP9 signaling pathways in Philadelphia chromosome-positive CML hemangioblasts [13-15]. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.